Personalized radiation strategy tested for advanced throat cancer
NCT ID NCT07248696
Summary
This study is testing whether adding a drug called tislelizumab to standard chemotherapy, followed by a personalized radiation plan, can better control advanced nasopharyngeal cancer that has already spread. It enrolled 32 adults whose tumors shrank after initial chemo-immunotherapy. The goal is to see if this approach helps keep the cancer from growing back longer and is safe for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CANCINOMA (NPC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, 400000, China
Conditions
Explore the condition pages connected to this study.